Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.Financial_Report.xls
10-Q - GENESIS BIOPHARMA FORM 10-Q - Lion Biotechnologies, Inc.gnbp10q093012.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R28.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R25.htm
EX-31.2 - EXHIBIT 31.2 - Lion Biotechnologies, Inc.ex312.htm
EX-31.1 - EXHIBIT 31.1 - Lion Biotechnologies, Inc.ex311.htm
EX-32.1 - EXHIBIT 32.1 - Lion Biotechnologies, Inc.ex321.htm
EX-32.2 - EXHIBIT 32.2 - Lion Biotechnologies, Inc.ex322.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R26.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R27.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Lion Biotechnologies, Inc.R12.htm
v2.4.0.6
NOTE 3. 12% SECURED PROMISSORY NOTES
9 Months Ended
Sep. 30, 2012
Notes to Financial Statements  
NOTE 3. 12% SECURED PROMISSORY NOTES

 

NOTE 3.  12% SECURED PROMISSORY NOTES

 

On April 5, 2012, the Company issued two (2) twelve (12%) percent promissory notes in the aggregate amount of $250,000 (each a “Promissory Note”) that mature upon the earlier of a sale of $1,000,000 or more of the Company’s securities or May 4, 2012 (the “Maturity Date”). In the event the Company fails to repay the Promissory Notes by the Maturity Date, the Promissory Notes shall thereafter bear interest at a rate of eighteen (18%) percent until paid in full. The Promissory Notes may be prepaid by the Company at any time if paid in full. Specifically, the Company issued Ayer Capital Partners Master Fund L.P. a Promissory Note in the principal sum of $245,000 and Ayer Capital Partners Kestrel Fund L.P. a Promissory Note in the principal sum of $5,000. Ayer Capital Partners Master Fund L.P. currently owns $2,706,146 of the Company’s Tranche A Senior Secured Convertible Promissory Notes and Tranche B Senior Secured Convertible Promissory Notes and Ayer Capital Partners Kestrel Fund L.P. currently owns $76,324 of the Company’s Tranche A Senior Secured Convertible Promissory Notes and Tranche B Senior Secured Convertible Promissory Notes. On May 7, 2012 these promissory notes were exchanged for new notes described below.

 

From May to July 2012, we entered into Note and Common Stock Subscription Agreement (the “Subscription Agreement”) with accredited investors (collectively, the “Purchasers”) in connection with the subscription by the Purchasers for certain Secured Promissory Notes (the “2012 Secured Notes”) and shares of our common stock.

 

The 2012 Secured Notes bear an interest of 12% per annum, mature and were due and payable in full on the earlier of (i) June 30, 2012, (ii) the date on which the Company has, after May 7, 2012, raised capital (debt or equity) equal to or greater than $1,500,000 in the aggregate, or (iii) a sale and/or merger of the Company.  The repayment of the 2012 Secured Notes is secured with a first lien on all of the assets of the Company, which lien will be parri passu with the Company’s other current and future senior lenders.  In addition, the 2012 Secured Notes are secured by a pledge of all of the shares of Common Stock and by all Common Stock purchase options owned by the Company’s current chief executive officer/ president. Subsequent to the notes issuance, the note maturity date was amended several times and was extended to December 31, 2012. Except for the change of the maturity date, all of the original terms and conditions of the Notes remain in full force and effect.  Furthermore, the Subscription Agreement provides that if, at any time while the 2012 Secured Notes are outstanding, we consummate any equity and/or debt financing whereby the terms of such financing are more favorable than those provided in the 2012 Secured Notes, then the remaining outstanding portion of the credit facility shall be adjusted to have such terms and conditions similar to those of the new financing. Total cash proceeds received during the period amounted to $981,250. In addition, the $250,000 in notes were exchanged as described above for a total of $1,231,250 in new notes.

 

Upon issuance of the notes, the Company was required to issue 615,625 shares of its common stock.  The Company determined the fair value of the common stock to be issued was $497,888 based upon the trading price of the Company’s common stock and recorded a corresponding discount to the Notes.  The note discount was amortized in full over the original maturity date of the notes and recorded part of “Amortization of discount on Notes” in the accompanying statement of operations.

 

As of September 30, 2012, $1,231,250 remains outstanding and $57,351 in accrued interest which is recorded as part of Accounts Payable and Accrued Expenses in the accompanying condensed balance sheet.

 

As of the date of this Quarterly Report, the notes are currently past due and the Company is in default.  The Company has not received any demand for payment from the note holders and is currently in discussion to cure the default.